Dan Neville (Limerick, Fine Gael)
Link to this: Individually | In context

Question 234: To ask the Minister for Health if the Vertex created Kayldeco drug for people with Cystic Fibrosis, with the G155D mutation, is available through the health services under the long term illness scheme. [32540/12]

Róisín Shortall (Dublin North West, Labour)
Link to this: Individually | In context

Ivacaftor (Kalydeco) received a positive opinion from the Committee for Medicinal Products for Human Use at EU level in May 2012. Marketing authorisation issued by the EU Commission is anticipated in due course. Should the manufacturers make an application for inclusion of the product on the GMS and community drugs schemes, that application shall be considered in accordance with the relevant criteria.